We are live on ! Find out more
INBX icon

Inhibrx

163 hedge funds and large institutions have $1.36B invested in Inhibrx in 2026 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 56 increasing their positions, 39 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

596% more call options, than puts

Call options by funds: $31.9M | Put options by funds: $4.59M

148% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 21

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

59% more capital invested

Capital invested by funds: $855M → $1.36B (+$503M)

44% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 39

21% more funds holding

Funds holding: 135163 (+28)

10.64% more ownership

Funds ownership: 87.04%97.68% (+11%)

Holders
163
Holders Change
+28
Holders Change %
+20.74%
% of All Funds
1.96%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
52
Increased
56
Reduced
39
Closed
21
Calls
$31.9M
Puts
$4.59M
Net Calls
+$27.4M
Net Calls Change
+$3.68M

INBX Hedge Fund Activity: Q2 2026 in Review

163 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Inhibrx (INBX) for Q2 2026, worth a combined $1.36B — up 59% from $855M a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new INBX positions and 21 closed out — a net gain of 31 holders — while 56 added to existing stakes and 39 trimmed.

The largest buyer was Bank of America, adding an estimated $81M. The largest seller was Viking Global Investors, cutting an estimated $31.4M.

  • 163 institutional investors held Inhibrx (INBX) as of Q2 2026, up from 135 in Q1 2026.
  • Funds reported $1.36B of Inhibrx stock for Q2 2026, up 59% quarter-over-quarter.
  • 52 funds opened new Inhibrx positions in Q2 2026 and 21 closed out, a net change of +31 holders.
  • The largest Inhibrx buyer in Q2 2026 was Bank of America, an estimated $81M added.
  • The largest Inhibrx seller in Q2 2026 was Viking Global Investors, an estimated $31.4M sold.

Based on aggregated 13F filings for Q2 2026.